Navigation Links
MannKind Corporation Response to Recent Market Events
Date:3/10/2008

early differentiate it from existing diabetes compounds, whether the ability of Technosphere(R) Insulin to mimic the normal physiologic release of meal-time insulin will provide treatment advantages that will support regulatory approval and, if approved, physician and patient adoption, difficulties or delays in seeking or obtaining regulatory approval, whether MannKind will be able to enter into and maintain a collaboration with a pharmaceutical partner for commercialization of Technosphere(R) Insulin and its other peptide hormone drug candidates on attractive terms for MannKind if at all, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2006 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... SAN FRANCISCO, Calif., Aug. 27 Poniard,Pharmaceuticals, Inc. ... oncology, today announced that Jerry McMahon, Ph.D., chairman ... September during which he,will provide a corporate overview, ... picoplatin, the Company,s lead product candidate., -- ...
... and MILPITAS, California, August 27, Peakdale Molecular ... chemistry services to the pharmaceutical and,biotechnology industry, ... unique,and cost-effective provider of products and systems ... of AssayReady4U(TM)., AssayReady4U(TM) is an online ...
... INDIANAPOLIS, Aug. 26 Amylin,Pharmaceuticals, Inc. (Nasdaq: AMLN ... ),in a conference call today provided context and additional ... Administration (FDA),update to a prior alert for BYETTA(R) (exenatide) ... cases referenced,in the alert, as well as others, and ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 2Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:4/17/2014)... KAN. A Kansas State University engineer has ... and remotely detects improvised explosive devices. The same ... William Dunn, the Steven M. and Kay L. ... mechanical and nuclear engineering, and his research team ... hidden underground or in car trunks. The distance ...
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
(Date:4/17/2014)... the Amazon help create tinderbox conditions for wildfires ... forest loss during drought years, according to a ... in the Amazon could reach a "tipping point" ... to large-scale loss of trees, making recovery more ... Penn State. , "We documented one of the ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... could also be giving us bad breath, according to research ... Medical Microbiology . For the first time, scientists have found ... who are not showing signs of stomach disease. The ... some of which can cause disease. Helicobacter pylori ...
... set of proteins known as cannabinoid receptors, which ... body also has chemicals known as endocannabinoids that ... (AEA) and 2-arachidonoylglycerol (2-AG). These natural components of ... efforts to develop new treatments not only for ...
... Buenos Aires, Argentina Current research suggests that melatonin ... disease. The related report by Sande et al., "Therapeutic ... December issue of The American Journal of Pathology ... pain in their eyes, and their vision rapidly deteriorates. ...
Cached Biology News:Stomach ulcer bug causes bad breath 2Scripps research team defines new painkilling chemical pathway 2Melatonin may save eyesight in inflammatory disease 2
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Biology Products: